Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells

Abstract Background Immune checkpoint inhibitors are approved for the treatment of various tumors, but the response rate is not satisfactory in certain malignancies. Inhibitor of apoptosis proteins (IAP) ubiquitin-E3 ligase activity is involved in the regulation of immune responses. APG-1387 is a no...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Wentao Pan, Qiuyun Luo, Eric Liang, Mude Shi, Jian Sun, Huimin Shen, Zhenhai Lu, Lin Zhang, Xianglei Yan, Luping Yuan, Suna Zhou, Hanjie Yi, Yifan Zhai, Miao-zhen Qiu, Dajun Yang
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-05-01
סדרה:	Cancer Cell International
נושאים:	Smac mimetic APG-1387 Combination therapy Immunotherapy CD3 + NK1.1 + cells
גישה מקוונת:	https://doi.org/10.1186/s12935-024-03373-7
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!